Articles

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
The Sackler Faculty of Medicine, Tel Aviv University, Israel
Department of Hematology, Alberts Schweitzer Hospital, Dordrecht, the Netherlands
Department of Hematology, Ankara University School of Medicine, Turkey
Unit of Hematology, University Hospital of Amiens, France
Division of Hematology, Chaim Sheba Medical Center, Tel Hashomer, Israel
Área de Oncología. Unidad de Oncología Médica, E.P. Hospital Costa del Sol, Marbella, Spain
Hematology Unit, Santa Maria Delle Croci Hospital, Ravenna, Italy
Hematology Department, Ondokuz Mayis University, Samsun, Turkey
PDMA Operations (Biometrics), F. Hoffmann-La Roche Ltd., Basel, Switzerland
Pharma Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland
Department of Internal Medicine I, University Hospital of Saarland, Homburg, Germany
Vol. 102 No. 11 (2017): November, 2017 https://doi.org/10.3324/haematol.2017.173583